Coherus Oncology, Inc. (CHRS)
(Delayed Data from NSDQ)
$1.61 USD
+0.08 (5.23%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $1.61 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CHRS 1.61 +0.08(5.23%)
Will CHRS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CHRS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CHRS
Coherus Oncology (CHRS) Reports Q2 Loss, Beats Revenue Estimates
Arcus Biosciences, Inc. (RCUS) Reports Break-Even Earnings for Q2
CHRS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Strength Seen in Krystal Biotech (KRYS): Can Its 4.2% Jump Turn into More Strength?
Coherus BioSciences (CHRS) Reports Q1 Loss, Lags Revenue Estimates
Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates
Other News for CHRS
CHRS forms Golden Cross on September 19
Is CHRS set to rally? Expansion Breakout shows up after rocketing 13.33%
CHRS falls 0.74% on September 17, leaving the technical picture intact
CHRS's price rises by 7.09% on September 16, though its technical setup remains stable.
MACD Bearish Signal Line Cross appears for CHRS after 1.55% move